SurvivorNet on MSN
The evERA Trial: A Promising Treatment Option For Patients With Estrogen Receptor-Positive (ER+), HER2-Negative (HER2-) Breast Cancer
The evERA breast cancer trial marks a turning point for some patients with a specific type of advanced breast cancer known as ...
Please provide your email address to receive an email when new articles are posted on . Endocrine Today has compiled a list of recent FDA news stories relating to endocrine practice. Drugs under ...
As the only pituitary-directed therapy, Signifor represents a novel therapeutic approach by addressing the underlying mechanism of Cushing's disease[1] In the Phase III trial, most patients ...
The best weight loss medication for men includes semaglutide (Ozempic , Wegovy ), tirzepatide (Mounjaro , Zepbound ), and compounded GLP-1s. The best weight ...
MedPage Today on MSN
Overcoming CDK4/6 Inhibitor Resistance in HR-Positive/HER2-Negative Breast Cancer
In the CAPItello-291 trial of capivasertib plus fulvestrant, 73% of patients had already received a CDK4/6 inhibitor. As ...
Heart failure and type 2 diabetes are exquisitely intertwined. Their shared pathophysiology can accelerate debilitating outcomes for patients that clinicians struggle to prevent and treat. People with ...
Researchers have discovered an unexpected relationship between levels of the amino acid leucine (found in beef, chicken, pork and fish and other foods) and the development of tamoxifen resistance in ...
LONDON--(BUSINESS WIRE)--Technavio has been monitoring the endocrinology drugs market and it is poised to grow by USD 24.78 billion during 2020-2024, progressing at a CAGR of almost 7% during the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback